Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Jan 31, 2020

SELL
$4.69 - $13.45 $3,508 - $10,060
-748 Closed
0 $0
Q3 2019

Oct 31, 2019

BUY
$9.41 - $16.56 $7,038 - $12,386
748 New
748 $9,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.77B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Dorsey Wright & Associates Portfolio

Follow Dorsey Wright & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dorsey Wright & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Dorsey Wright & Associates with notifications on news.